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We read with interest the recent meta-analysis by Davis et al (1) on the blood pressure (BP) 
lowering effects of renal denervation (RDN) in treatment-resistant hypertensive patients.  The 
authors computed pooled statistics for 3 so-called controlled studies and 9 observational studies.  
They concluded that the 6-month reductions in systolic/diastolic BP in response to RDN aver-
aged 28.9/11.0 mmHg and 25.0/10.0 mmHg in the controlled and observational studies, respec-
tively.  A number of issues need clarification.   
First, Dr. Davis used the term controlled to group 2 randomized trials (2,3) and one observational 
study (4).  It is questionable whether truly randomized trials and a nonrandomized study can be 
combined into a single group.  Moreover, one of the randomized studies was of low quality (2).  
Sample size and primary and secondary endpoints changed across successive design protocols 
posted at http://www.clinicaltrials.gov up to 1 year after the paper was published (2).  We feel 
that this study (2) should have been excluded based on CONSORT quality standards (5).  Fur-
thermore, the spread of the BP responses was not reported for the control group in SYMPLICITY 
HTN-1(4).  In Dr. Davis’ Figure 2, the numerical data for the 6-month systolic responses are 
switched between 2 studies.  Moreover, there is discordance between the SDs reported in Dr. 
Davis’ Figure 2 (systolic/diastolic responses at 6 months SD, 9.8/6.0) and the spread of the BP 
responses in Figure 5 (4.8/3.0 at 6 months) and in the text (5.0/2.0 mmHg at 12 months) of Poku-
shalov’s article.  Without clarification, these observations invalidate the pooled estimates for the 
controlled studies in Dr. Davis meta-analysis, because they were weighted for the inverse of the 
variance in individual studies.   
Second, turning to the 8 uncontrolled studies with 6-month data reported in Figure 3 of Dr. Da-
vis’ meta-analysis, 6 had very small sample size with follow-up data available in less than 20 
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patients (range, 8–20).  Small studies with positive results are more readily reported than larger 
studies with negative results.  Davis set a follow-up rate of less than 70% – not greater than 70% 
as stated in his paper – as the limit to determine high risk of bias.  In fact the 6-month follow-up 
rate in 4 small studies with 10 up to 20 participants was 100%, but in all other studies it ranged 
from 53% to 66%.  The pooled estimates of the 6-month BP responses in uncontrolled group 
were based on office BP in 6 studies and 24-h ambulatory monitoring in 2 studies (6,7).  Results 
based on different techniques of BP measurement cannot be pooled in a single summary statistic.   
One wonders how a meta-analysis including only a single randomized trial of sufficient quality 
(3) adds to current knowledge.  Dr. Davis concluded that RDN resulted in a substantial BP reduc-
tion at 6 months.  In our view, this conclusion does not hold in view of the above issues.  We 
believe that the main conclusion of Dr. Davis’ meta-analysis should have been that currently the 
evidence in favor of RDN in treatment-resistant hypertension is of very low quality, that a meta-
analysis cannot replace properly sized randomized clinical trials, and that RDN therefore should 
not be applied in routine clinical practice.  
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